GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care
Jennifer Manne‐Goehler, Felix Teufel, François Venter
Abstract
This Viewpoint discusses the optimal treatment duration of glucagon-like peptide-1 receptor agonists in people with obesity and the benefits of off-ramping, the tapering of these antiobesity medications following an initial treatment period.
Topics & Concepts
MedicineTaperingGlucagon-like peptide 1 receptorObesityGlucagon-like peptide-1AgonistReceptorDuration (music)Internal medicineEndocrinologyDiabetes mellitusPharmacologyType 2 diabetesArtComputer graphics (images)LiteratureComputer sciencePharmacology and Obesity TreatmentDiabetes Treatment and ManagementDiet and metabolism studies